â Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes

â A digital image analysis evaluating glabellar line severity and brow position following treatment with investigational trenibotulinumtoxinE (trenibotE) and BOTOX® Cosmetic (onabotulinumtoxinA) will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session

â Expert panel to explore shifting consumer expectations, common misconceptions and medical weight loss in aesthetics, drawing on insights from the Allergan Aesthetics "What Consumers Really Want" report

IRVINE, Calif., Nov. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, underscoring the company's continued investment in generating scientific evidence to inform care across multiple aesthetic categories. The presentations include new data from two Phase 4 studies examining aesthetic treatment in patients on glucagon-like peptide-1 (GLP-1)-related medications for weight management, with a focus on patient satisfaction and psychosocial outcomes. Additional presentations span multimodal aesthetic treatment across diverse patient populations, neurotoxin innovation, body contouring and skin quality, including exosome research.

"Advancing aesthetic medicine starts with understanding patients' evolving needs and generating the scientific evidence to keep pace," said Darin Messina, Ph.D., senior vice president, head of aesthetics research and development, AbbVie. "We continue to build on our extensive body of clinical research, including studies of multimodal treatment approaches, to help providers make informed decisions about using our products to address a range of aesthetic concerns."

Two video oral abstract presentations will share new data from Phase 4 studies exploring aesthetic treatment in patients taking GLP-1-related medications for weight loss, with research examining facial appearance, skin quality, patient satisfaction and psychosocial outcomes:

- HARMONY IN DIVERSITY: Improved Satisfaction With Aesthetic Appearance and Psychosocial Function Following Multimodal Aesthetic Treatment in a Medical Weight Loss Cohort

- Satisfaction With Overall Facial Appearance and Psychological Outcomes After Treatment With Hyaluronic Acid Injectables in Patients With Medical Weight Loss

"Patients experiencing medical weight loss may have aesthetic concerns that extend beyond changes in facial volume or skin quality," said Joely Kaufman-Janette, M.D., board-certified dermatologist, Skin Research Institute, and study investigator. "By examining patient satisfaction and psychosocial well-being alongside changes in physical appearance, we can gain a more complete picture of their needs and support them with individualized treatment approaches throughout their aesthetic journeys."

A digital image analysis of glabellar line severity and brow position following treatment with investigational trenibotE and BOTOX® Cosmetic will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session at 7:30 a.m. PT on Sunday, Nov. 8. The analysis uses objective digital imaging to add quantitative measures that complement clinician assessment.

- Similar Clinical Outcomes in Glabellar Line Severity and Brow Position Following TrenibotE and OnabotA Treatment: A Digital Image Analysis (presented by Jean Carruthers, M.D. on behalf of Shannon Humphrey, M.D.)

Allergan Aesthetics will also host The Aesthetics Evolution: Inside the Changing Consumer Landscape expert panel at 12:30 p.m. PT on Thursday, Nov. 5, in the Special Events Room. Drawing on insights from the company's "What Consumers Really Want" report, the panel will examine shifting consumer expectations, common misconceptions and medical weight loss in aesthetics. Tiffany Libby, M.D., will moderate the panel, featuring Anthony Rossi, M.D.; Joely Kaufman-Janette, M.D.; and Vince Bertucci, M.D.

Other presentations from Allergan Aesthetics highlight new data on multimodal aesthetic treatment of the face and neck across a diverse patient population, including patient-reported satisfaction and psychosocial outcomes; the use of a topical cosmetic human fibroblast-derived exosome serum to support skin quality, both as part of a daily skincare regimen and alongside in-office procedures such as radiofrequency microneedling, non-ablative laser and diamond tip microdermabrasion; and how treatment sequence may influence outcomes and patient experience when combining cryolipolysis and electromagnetic muscle stimulation for abdominal body contouring.

A full list of Allergan Aesthetics' presentations is below.

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

- Moderate to severe lateral canthal lines associated with orbicularis oculi activity

- Moderate to severe forehead lines associated with frontalis activity

- Moderate to severe platysma bands associated with platysma muscle activity

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

CONTRAINDICATIONS

BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS

Lack of Equivalency Between Botulinum Toxin Products

The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. BOTOX® Cosmetic is not equivalent to other preparations of botulinum toxin products, and therefore, Units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, discontinue further injection of BOTOX Cosmetic and immediately institute appropriate medical therapy. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System

There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including preexisting cardiovascular disease. Use caution when administering to patients with preexisting cardiovascular disease.

Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders

Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).

IMPERIAL HEALTH PLAN OF CALIFORNIA, INC. (HMO) (HMO SNP) NAMED ONE OF THE BEST MEDICARE ADVANTAGE PLANS IN CALIFORNIA 2027 BY FORBES ADVISOR

News provided by

Imperial Health Plan of California, Inc & Affiliated Companies

Nov 03, 2026, 08:00 ET

Independent analysis of 290 California plans recognizes Imperial for quality, affordability, and statewide access.

PASADENA, Calif., Nov. 3, 2026 /PRNewswire/ -- Imperial Health Plan of California, Inc. (Imperial) today announced it has been named one of the Best Medicare Advantage Plans in California 2027 by Forbes Advisor. Imperial earned a 4.8 out of 5 rating from Forbes Advisor's research team, the second-highest rating among the five companies recognized, and its Imperial Dynamic Plan (HMO) was named the company's top-rated plan.

The recognition comes from Forbes Advisor's own independent evaluation of 290 Medicare Advantage plans in California, which weighed plan-level quality and cost, CMS star ratings, enrollment share, and county coverage. It arrives as Medicare beneficiaries across the state are comparing their options during the annual Open Enrollment period.

"Being recognized by Forbes Advisor is a meaningful moment for everyone at Imperial," said Dr. Paveljit Bindra, CEO of Imperial. "Their team looked at quality, cost, and access together, which is exactly how our members experience their health plan," added Sue Dahlkamp, Vice President for Member Experience. "This recognition reflects our mission to make healthcare more personal, more coordinated, and more accessible for every member we serve," according to Muthukumar Vaidyaraman, MD, Chief Medical Officer.

Forbes Advisor highlighted two strengths in particular. The Imperial Dynamic Plan (HMO) carries a $295 maximum out-of-pocket cost, the lowest among the plans Forbes Advisor featured, and it is available in 51 California counties, the broadest availability on the list.

View the full rankings at: https://www.forbes.com/advisor/health-insurance/medicare/medicare-advantage-in-california/

Imperial currently serves members in 51 of California's 58 counties, offering high value, coordinated care through an extensive provider network. Its approach emphasizes whole-person wellness with innovative benefits such as in-home diagnostic testing, prescription delivery, expanded transportation, and generous Over-the-Counter (OTC) allowances, which are all designed to help members stay healthy in body, mind, and spirit.

During Medicare's Open Enrollment period (October 15 to December 7), we invite current and prospective members, along with broker partners, to explore Imperial's plan options, shop, compare, and enroll at https://imperialhealthplan.com/.

"Recognition from two independent sources this season tells us our approach is working," said Andranik Barsegyan, Senior Director for Quality. Evelyn Cho, PharmD, Senior Director for Pharmacy Operations added that, "Our focus remains on keeping care affordable, expanding access, and improving the member experience year after year."

About Imperial

Imperial is a California-based health plan offering Medicare Advantage coverage to older adults and other eligible individuals across much of the state. Imperial's mission is to empower members to achieve their full potential by keeping them healthy in body, mind, and spirit through a community-focused medical and pharmacy model of whole-person care. Learn more at https://imperialhealthplan.com/.

About Forbes Advisor: Best Medicare Advantage Plans in California

Forbes Advisor evaluates Medicare Advantage providers at the state level using a data-driven methodology. Providers are scored on average plan score (50%), which includes Part C and Part D costs, CMS star ratings, and value measures; average CMS star rating (30%); provider enrollment share (10%); and provider county coverage (10%).

Media Contact:

Sue Dahlkamp

Vice President, Member Experience

Imperial Health Plan of California, Inc. & Affiliated Companies

[email protected]

H5496_515 Forbes Press Release_M ENG Accepted 10/25/26

SOURCE Imperial Health Plan of California, Inc & Affiliated Companies

Share this article

Two New Bowls and Two New Smoothies Debut a Nutrient-Rich Cacao Base Naturally Sweetened with Dates and Zero Added Sugar

BELMAR, N.J., Nov. 3, 2026 /PRNewswire/ -- Playa Bowls® is making chocolate waves with the launch of Cacao Chocolate Waves, a four item seasonal menu built around its all-new Playa Cacao Base. Rich, smooth, decadent and seriously chocolatey, the new base gives chocolate lovers plenty of reasons to treat themselves with two new bowls and two new smoothies. Made with cacao and naturally sweetened with dates, the new Playa Cacao Base contains zero added sugar.

Beyond its rich chocolate flavor, cacao is a superfood that naturally contains antioxidants, flavonoids and essential minerals, with benefits that support heart health, brain function, metabolic balance and mood.

"Who doesn't want a little chocolate this time of year? Amid the hustle and bustle of the holidays, everyone deserves a moment of bliss, a chance to slow down and savor something irresistibly smooth," said Danielle DeAngelo, director of research and development at Playa Bowls. "Our new Playa Cacao Base satisfies that chocolate craving while bringing the nutritional benefits of cacao, a superfood in its own right. We hope everyone enjoys these beautiful, must-try seasonal bowls and smoothies."

Beginning November 3, guests can enjoy Cacao Chocolate Waves at Playa Bowls shops nationwide. The menu features:

- Chocolate Coconut Joy Bowl: Half Playa Cacao Base and half Playa Coconut® Base topped with blueberry flax granola, potassium-rich banana, walnuts and a Nutella® drizzle, pairing rich chocolate and creamy coconut with nutty crunch and a chocolate-hazelnut finish, plus electrolytes and healthy fats from coconut.

- Chocolate Covered Strawberry Bowl: Half Playa Cacao Base and half Stupid Cupid Base, a pink blend of strawberry, banana and organic coconut milk, topped with blueberry flax granola, fresh strawberries, banana and a dollop of coco whip, creating a striking chocolate-and-pink contrast and a romantic pairing of rich chocolate and fresh strawberry inspired by the decadence of a classic chocolate-covered strawberry.

- Triple Dark Wave Smoothie: Playa Cacao Base, Playa Coconut® Base, banana, chocolate protein, Nutella® and organic coconut milk blended to a velvety finish with an additional Nutella® swirl, bringing together deep cacao, chocolate-hazelnut flavor and a touch of coconut, plus electrolytes and healthy fats from coconut.

- PB Chocolate Wave Smoothie: Playa Cacao Base, banana, chocolate protein, peanut butter and organic coconut milk blended and finished with peanut butter and coco whip swirls, creating a marbled finish over the classic pairing of chocolate and peanut butter, with potassium and natural carbs from banana for sustained energy.

To learn more about Playa Bowls, visit www.playabowls.com and follow along on Instagram, TikTok and Facebook for the latest updates.

ABOUT PLAYA BOWLS

Playa Bowls is the nation's leading superfruit bowl shop serving up an extensive and unique menu of over 40 items, including the bright flavors of acai, mango, pitaya, green, and coconut bowls alongside better-for-you refreshers, oatmeal bowls, juices, smoothies, and cold brew made with the freshest, high-quality ingredients. What began as a pair of blenders, a patio table, and a fridge in 2014 has flourished into more than 400 shops nationwide that operate in 32 states, thousands of team members, and a mission to lead communities in healthy, sustainable living. The rapidly growing franchise has received numerous accolades, including No. 7 on the 2026 Franchise Times Fast & Serious List, placement on Entrepreneur magazine's 2026 Franchise 500, Forbes 30 Under 30, Fast Casual's Top 100 Movers & Shakers 2026, QSR Young Leaders to Watch, and recognition as a finalist for the Ernst & Young Entrepreneur of the Year Award. Visit playabowls.com for additional information and stay connected on Instagram, TikTok, and Facebook. For more information on franchising, please visit franchise.playabowls.com/.

While supplies last. NUTELLA® is a registered trademark of Ferrero S.p.A. Playa Coconut® is a registered trademark of Playa Bowls IP, LLC. © 2026 Playa Bowls IP, LLC. All rights reserved.

SOURCE Playa Bowls

Share this article

Vanuch will also lead contracts and acquisition strategy to support VIA's expansion across

defense, public safety, and commercial markets

BOSTON, Nov. 3, 2026 /PRNewswire/ -- VIA Science, Inc. (VIA), a leading software provider to defense, law enforcement, and humanitarian organizations, today announced the appointment of David Vanuch as Senior Vice President of Contracts and Government Affairs. Vanuch brings more than 20 years of acquisition, contracting, and procurement leadership, including senior roles with the National Guard Bureau (NGB), the Executive Office of the President, the U.S. Air Force Rapid Capabilities Office (RCO), and the Federal Bureau of Investigation (FBI) supporting classified and mission-critical programs. He joins VIA from C3.ai, where he was Head of Contracts and Capture for defense, national security, and commercial AI programs.

"Customers need a clear path to acquire and deploy the technology their missions demand," said Colin Gounden, co-founder and CEO of VIA Science. "David brings deep acquisition expertise and an understanding of how government operates. His leadership will help VIA turn customer interest into executable contracts, agreements, and broader adoption."

As VIA further expands across government, law enforcement, and humanitarian organizations, Vanuch will lead the company's contracts and government affairs strategy and build scalable processes that make it easier for customers and partners to adopt VIA's technology. In his role, Vanuch will also guide VIA's engagement with government stakeholders, advise on data rights and intellectual property protections, and build out the company's contracts and government affairs team as it grows.

"VIA is solving a challenge I have seen throughout my career: organizations need to put sensitive data to work without compromising security or control," said Vanuch. "My focus is on aligning acquisition strategy, government engagement, and customer agreements so customers can adopt VIA's technology efficiently while we protect the intellectual property that supports our growth."

Earlier in his career, Vanuch was the Senior Contracting Official for the National Guard Bureau, where he advised Senior NGB Leadership on more than $5 billion in annual contracting across the 50 states, three territories, and the District of Columbia. He led a team of more than 200 acquisition professionals responsible for roughly 20,000 contract actions each year. He also held leadership roles at the FBI and the U.S. Airforce RCO, and served nearly 20 years in the United States Marine Corps, rising to the rank of Gunnery Sergeant and holding communications and security leadership roles supporting mission-critical operations.

About VIA

Headquartered in Boston, VIA provides mission-critical software for secure data exchange and trustworthy AI without compromising speed, simplicity, or resilience. Its military-grade architecture helps defense, public safety agencies, and humanitarian organizations use AI while maintaining control of sensitive, distributed data even in contested or offline environments.

SOURCE VIA Science, Inc.

Share this article

Randall W. Atkins Elected as Chairman of the International Energy Agency's Coal Industry Advisory Board

LEXINGTON, Ky., Nov. 3, 2026 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB) ("Ramaco" or the "Company") announced today that its Chairman and Chief Executive Officer, Randall W. Atkins, has been elected to serve as the Chairman of the International Energy Agency's (IEA) Coal Industry Advisory Board (CIAB) based in Paris, France.

Atkins was elected for the chairmanship by a unanimous vote of both the CIAB Executive Committee and its full membership, reflecting the CIAB's strong support for his leadership and experience in the international coal, energy and critical minerals sectors.

The CIAB, created in 1979, is the oldest advisory board of the IEA and brings together senior leaders from the global coal, power and critical mineral industries to provide industry perspectives and advice to the International Energy Agency on issues involving coal, energy security, power, technology, markets, critical minerals and related governmental policy.

"I am deeply honored by the confidence of my CIAB colleagues and especially grateful for their unanimous support to work with them advising in the IEA on matters of importance on our industry," said Atkins. "The world has entered a period in which energy, power, electrification and mineral security are both intertwined and of increasingly vital importance. Coal must continue to play its historically essential role in global steelmaking and energy production. At the same time, new technologies are also creating opportunities for coal to serve as a source of rare earths and critical minerals as well as a feedstock for higher value advanced carbon products. I keenly look forward to working with the IEA and my colleagues on the CIAB to advance a thoughtful discussion about coal's evolving role and its continued critical importance in the energy dialogue."

The CIAB chairmanship also expands Atkins' prior role in national and international energy policy. Atkins previously served as the immediate past Chairman of the U.S. Department of Energy's National Coal Council (NCC). In December 2025, Secretary of Energy Chris Wright appointed Atkins to an additional term as an NCC member. The NCC advises the Secretary of Energy on scientific, technical and programmatic matters relating to coal and coal policy.

Atkins brings more than 40 years of experience in energy and commodity-related development, investment and financing to his new role. He is a founder of Ramaco and serves as Chairman and Chief Executive Officer. Before forming Ramaco, Atkins was a banker with J.P. Morgan & Co. and held a variety of investment banking and private equity positions focused on the mining and energy industries.

His career has increasingly focused on expanding the strategic role of coal beyond its traditional markets to include advanced carbon products, rare earth elements and critical minerals. He has testified before the energy committees of both the United States Senate and House of Representatives and serves on the Board of Directors of the National Mining Association. Atkins earned a B.A. from Duke University and a J.D. from Washington & Lee University School of Law.

Jenkins to Chair CIAB Associate Members

The CIAB structure provides for each Board member to designate an Associate Member who works alongside the member and participates in the activities and work of the Board.

Atkins has designated Ramaco Vice Chairman Evan Jenkins as his Associate Member. As a result of Atkins assuming the chairmanship of the CIAB, Jenkins will also assume the corresponding leadership role as Chair of the CIAB Associate Members.

"Randy's unanimous election by the Executive Committee and full membership is an important recognition of both his leadership and his vision for the future of coal," said Jenkins. "His leadership roles with both the CIAB and the National Coal Council provide a unique opportunity to help advance a broader discussion about coal's future. I am honored to work with Randy and serve as the Chair of the CIAB Associates. I look forward to working in that role of supporting the work of the Board."

ABOUT THE IEA COAL INDUSTRY ADVISORY BOARD

The Coal Industry Advisory Board was established by the International Energy Agency in 1979. The CIAB provides industry expertise and advice to the IEA, with a current focus that includes reliable and affordable energy, the energy transition, grid stability, carbon capture, utilization and storage (CCUS) and critical minerals.

ABOUT RAMACO RESOURCES

Ramaco Resources, Inc. is an operator and developer of high-quality, low-cost metallurgical coal in southern West Virginia and southwestern Virginia and exploring a coal, rare earth and other critical minerals project in Wyoming. The Company's executive offices are located in Lexington, Kentucky, with operational offices in Charleston, West Virginia and Sheridan, Wyoming. The Company currently has four active metallurgical coal mining complexes in Central Appalachia and one coal mine and rare earth element and other critical mineral exploration stage property near Sheridan, Wyoming (the "Brook Mine"). The Brook Mine remains an exploration stage property, and no assurance can be given that it will be successfully developed into a commercial scale mine or that any inferred mineral resources estimated will be converted into higher confidence mineral resources or eventually mineral reserves. Contiguous to the Brook Mine, the Company operates a carbon research facility related to the potential production of advanced carbon products and materials from coal. In connection with these activities, it holds a body of more than 70 intellectual property patents, pending applications, exclusive licensing agreements and various trademarks. News and additional information about Ramaco Resources, including filings with the Securities and Exchange Commission, are available at https://www.ramacoresources.com. For more information, contact investor relations at (859) 244-7455 or [email protected].

POINT OF CONTACT

INVESTOR RELATIONS:

George Cpin

VP, Finance & Investor Relations

[email protected] or 859-244-7455

SOURCE Ramaco Resources, Inc.

Share this article

JUNO BEACH, Fla., Nov. 3, 2026 /PRNewswire/ -- XPLR Infrastructure, LP (NYSE: XIFR) has posted its third-quarter 2026 financial results in a news release available on the company's website at www.XPLRInfrastructure.com/FinancialResults.

Members of the company's senior management team will discuss the company's third-quarter 2026 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET today. The listen-only webcast will be available on XPLR Infrastructure's website by accessing the following link: www.XPLRInfrastructure.com/FinancialResults. A replay will be available for 90 days by accessing the link listed above.

XPLR Infrastructure, LP

XPLR Infrastructure, LP (NYSE: XIFR) is a limited partnership that has an ownership interest in a clean energy infrastructure portfolio with long-term, stable cash flows. XPLR Infrastructure is focused on delivering long-term value to its common unitholders through disciplined capital allocation of the cash flows generated by its assets and is positioning itself to benefit from the expected growth in the U.S. power sector. Headquartered in Juno Beach, Florida, XPLR Infrastructure's portfolio of contracted clean energy assets is diversified across generation technologies, including wind, solar and battery storage projects in the U.S. For more information, please visit: www.XPLRInfrastructure.com.

SOURCE XPLR Infrastructure, LP

Share this article

COLUMBUS, Ohio, Nov. 3, 2026 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) has created AEP Infrastructure, a new business unit focused on investing in, building and operating energy infrastructure to meet growing electricity demand. Greg Hall will lead the organization as president and will continue to report to Bill Fehrman, AEP chairman, president and chief executive officer.

AEP Infrastructure brings together the company's competitive generation, infrastructure development, and retail and wholesale energy capabilities to provide energy solutions for customers as electricity demand accelerates, driven by large-load customers and economic development to benefit communities.

"AEP Infrastructure builds on an already strong segment of our business and positions us to meet once-in-a-generation load growth, while delivering significant value to our stakeholders," Fehrman said. "Under Greg's leadership, this team will draw on its deep experience acquiring and developing energy infrastructure to respond to increasing demand and deliver for our customers."

The new organization will evaluate potential generation acquisitions to strengthen AEP's competitive portfolio and develop new generation resources backed by long-term customer contracts. These opportunities include the proposed acquisition of the Longview Power Plant and a recently announced 20-year agreement to develop a fuel cell facility for Google in Wyoming.

AEP Infrastructure also will include AEP Energy and AEP Energy Partners, which provide energy solutions for residential, commercial, industrial, data center and wholesale customers, and will develop potential opportunities for customer-owned transmission and distribution infrastructure. In his new role, Hall will continue to oversee potential asset acquisitions and regulated commercial operations for AEP's vertically integrated operating companies.

"AEP Infrastructure represents an exciting new chapter for our team, broadening our work to provide custom energy solutions and meet changing customer needs," Hall said. "I look forward to this opportunity to continue to innovate and evolve our work to create value for our stakeholders."

About AEP

AEP is committed to improving our customers' lives with reliable, affordable power. We expect to invest $100 billion from 2027 through 2031 to enhance service for customers and support the growing energy needs of our communities. Our nearly 18,000 employees operate and maintain the nation's largest electric transmission system with approximately 40,000 line miles, along with more than 253,000 miles of distribution lines to deliver energy to 5.6 million customers in 11 states. AEP also is one of the nation's largest electricity producers with approximately 34,000 megawatts of diverse owned and contracted generating capacity. We are focused on safety and operational excellence, creating value for our stakeholders and bringing opportunity to our service territory through economic development and community engagement. Our family of companies includes AEP Ohio, AEP Texas, Appalachian Power (in Virginia, West Virginia and Tennessee), Indiana Michigan Power, Kentucky Power, Public Service Company of Oklahoma, and Southwestern Electric Power Company (in Arkansas, Louisiana, east Texas and the Texas Panhandle). AEP also owns AEP Energy, which provides innovative competitive energy solutions nationwide. AEP is headquartered in Columbus, Ohio. For more information, visit aep.com.

SOURCE American Electric Power

Share this article

The Electron E1 enables edgeAI to significantly reduce energy consumption and BOM costs, while running complex AI models on-device

PITTSBURGH, Nov. 3, 2026 /PRNewswire/ -- Efficient Computer, the company building the world's most energy-efficient processors, today announced that edgeAI has selected the Electron E1 to develop high-performance, energy-efficient solutions for physical AI and critical infrastructure applications.

Electron E1 delivers higher performance and greater energy efficiency than many AI accelerators, with far greater programming flexibility. Electron E1 is also much more efficient than low-power CPUs, offering up to a 100X improvement in energy efficiency. This efficiency has enabled edgeAI to develop powerful solutions that run large AI models on-device while easing power, cost, and form-factor constraints. By removing energy consumption as a limiting factor, Electron E1 opens the door for edgeAI to deliver new AI capabilities and scale its solutions across a wide variety of markets.

"With our new funding and strong demand from a growing number of customers, including edgeAI, we're continuing to scale production of Electron E1," said Brandon Lucia, CEO and co-founder of Efficient Computer. "Electron E1 delivers better performance than an accelerator, with orders of magnitude greater energy efficiency, unlocking on-device capabilities that were previously out of reach for edgeAI."

edgeAI's transition to Electron E1 was seamless. Efficient's effcc Compiler maps customers' existing code to its dataflow architecture, allowing them to realize significant efficiency gains without rewriting code. Electron E1's programmable architecture also lets customers update applications in software, including through over-the-air updates so they can make changes as AI models and applications evolve. Its support for a range of popular programming languages and software frameworks gives customers flexibility in how they develop and deploy applications, unlike accelerators that can lock them into a single software stack.

"We evaluated a wide range of processors for our physical AI products, and none matched the Electron E1's combination of performance and efficiency. It runs our models in real time using a fraction of the power, while providing the same programming flexibility as any other processor," said Yang Jung Woong, CEO at edgeAI. "That gives our products the headroom to run the latest vision and compute stacks for years, something we couldn't support before. With Electron E1 now in volume production, the decision was clear: we committed to Electron E1 for our products and chose Efficient as our partner as we scale."

Electron E1 is ideal for a wide variety of applications that demand low power, high-efficiency, and powerful edge AI processing, including robotics and drones, critical infrastructure observability applications, and industrial wearables. With the company's recent $97 million Series B funding, Efficient is focused on bringing its groundbreaking energy efficiency up the compute stack.

About Efficient Computer

Efficient Computer builds the world's most energy-efficient general-purpose processor, combining ultra-efficient hardware with intuitive, developer-friendly software. Our technology scales from beyond-the-edge devices to datacenter systems, enabling industries to solve computing's energy challenge. For more information, visit https://efficient.computer.

About edgeAI

edgeAI builds proprietary AI semiconductors and edge AI technology that implements intelligent systems that operate immediately in the field. By connecting low-power, high-efficiency NPU designs with AIoT, robotics, video analysis, and remote control solutions, edgeAI provides AI infrastructure optimized for industrial, defense, agricultural, and smart city environments. By combining semiconductor development capabilities with field application technologies, edgeAI will lead the demonstration and commercialization of Korea's AI semiconductor ecosystem.

SOURCE Efficient Computer

Share this article

STAMFORD, Conn., Nov. 3, 2026 /PRNewswire/ -- Synchrony (NYSE: SYF) Chief Financial Officer, Brian J. Wenzel, will participate in a fireside chat at the KBW Fintech Ecosystem Conference on Tuesday, November 10, 2026 at 10:55 a.m. (Eastern Time) and the TD Cowen 2026 Financials & Fintech Conference on Tuesday, November 17, 2026 at 8:45 a.m. (Eastern Time).

A live webcast and replay will be made available on the Synchrony Investor Relations website at www.investors.synchrony.com

About Synchrony

Synchrony (NYSE: SYF) is a leading consumer financing company that has been at the heart of American commerce and opportunity for nearly a century. Synchrony delivers credit and banking products that empower tens of millions of consumers to improve their financial lives and access what matters most. Leveraging innovative solutions that are shaping the future of retail commerce, Synchrony supports the growth and success of some of the nation's most respected brands, alongside hundreds of thousands of small and midsize businesses, including health and wellness providers. Committed to excellence in service and culture, Synchrony is honored to be ranked the #1 Best Company to Work For® in the U.S. by Fortune magazine and Great Place to Work®. For more information, visit www.synchrony.com.

Contact:

Investor Relations     

Kathryn Miller                     

(203) 585-6291                   

Media Relations

Ashley Tufts

(203) 216-6277

SOURCE Synchrony

Share this article

FDA-approved neuroimmune modulation therapy is now available to eligible adults living with rheumatoid arthritis across New Mexico.

SANTA CLARITA, Calif., Nov. 3, 2026 /PRNewswire/ -- SetPoint® Medical, a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced the completion of the first SetPoint System procedures in New Mexico. The procedures were performed at University of New Mexico Hospital (UNM Hospital) in Albuquerque by neurosurgeon James Botros, M.D., who was also a surgical investigator in the RESET-RA study.

The SetPoint System is the first-and-only U.S. Food and Drug Administration (FDA)-approved neuroimmune modulation therapy for adults living with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response, loss of response, or intolerance to one or more biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs). It includes a miniaturized implantable neurostimulator that delivers targeted stimulation to the left vagus nerve, activating the body's innate anti-inflammatory pathways to help regulate the immune activity associated with RA. Patients charge the device at home using a wireless charger worn around the neck for a few minutes each week.

"Treating rheumatoid arthritis has not traditionally been part of a neurosurgeon's practice, and that is what makes this therapy so different," said Dr. Botros. "The vagus nerve plays an important role in regulating inflammation, and the SetPoint System allows us to engage that pathway directly. Having worked with this system since its clinical investigation, I look forward to seeing this collaboration with rheumatology continue to grow at UNM Hospital."

RA is a chronic autoimmune disease in which the immune system attacks healthy joint tissue, causing pain, swelling and bone erosion that can progress to deformity, reduced mobility and lasting disability. An estimated 1.5 million adults in the United States live with RA. There is no cure, and many patients continue to experience inadequately controlled disease or are unable to tolerate existing therapies, highlighting the need for novel treatment options.

The first patient treated with SetPoint System in New Mexico was referred by Hillary Norton, M.D. a rheumatologist and medical director at Inspire Santa Fe Medical Group. "Despite the number of advanced therapies available today, a significant group of my patients continue to live with active disease, side effects, or both," said Dr. Norton. "The SetPoint System gives those patients a treatment that works through a different mechanism than anything they have tried before, and that is an important addition to how we treat RA."

"Completing the first SetPoint System procedure in New Mexico adds another state to the growing list where SetPoint Therapy is available, and reflects our commitment to expanding access to neuroimmune modulation for people living with rheumatoid arthritis," said Murthy V. Simhambhatla, Ph.D., president and CEO of SetPoint Medical. "We are grateful to Dr. Botros, Dr. Norton and their teams for helping move RA care forward and for their commitment to people living with this disease."

About the SetPoint System

The SetPoint® System is indicated for use in the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response, loss of response, or intolerance to one or more biological or targeted synthetic disease modifying antirheumatic drugs. It should not be used if you have had a vagotomy or splenectomy, or if your healthcare provider determines that it is not safe for you to use the SetPoint System. Risks may include, but are not limited to, pain or infection after surgery, hoarseness, bruising, swelling, coughing and throat irritation.

For full safety information, please see Instructions for Use and our Important Safety Information at spm.care/ISI.

Individual results may vary.

About SetPoint Medical

SetPoint® Medical is a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases. The company's FDA-approved SetPoint System is the first neuroimmune modulation therapy available for people living with rheumatoid arthritis, offering a novel, device-based alternative for those who do not respond to or cannot tolerate biologic or targeted drug therapies. SetPoint's proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. With a vision to redefine the care of autoimmune conditions, SetPoint is also planning to evaluate its platform technology for other conditions including multiple sclerosis and Crohn's disease. Learn more at www.setpointmedical.com.

Dr. Botros and Dr. Norton have not been compensated in connection with this press release.

SOURCE SetPoint Medical

Share this article